

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	347	14	46	34	30	17	29
Week 2							
Evaluated	331	11	44	34	30	17	27
Retained	308/331 (93.1%)	11/11 (100.0%)	37/44 (84.1%)	34/34 (100.0%)	29/30 (96.7%)	16/17 (94.1%)	22/27 (81.5%)
On Time	305/308 (99.0%)	11/11 (100.0%)	37/37 (100.0%)	33/34 (97.1%)	29/29 (100.0%)	16/16 (100.0%)	21/22 (95.5%)
Late	3/308 (1.0%)	0/11 (0.0%)	0/37 (0.0%)	1/34 (2.9%)	0/29 (0.0%)	0/16 (0.0%)	1/22 (4.5%)
MissedVisit	21/331 (6.3%)	0/11 (0.0%)	7/44 (15.9%)	0/34 (0.0%)	1/30 (3.3%)	1/17 (5.9%)	5/27 (18.5%)
Lost to Follow-up	2/331 (0.6%)	0/11 (0.0%)	0/44 (0.0%)	0/34 (0.0%)	0/30 (0.0%)	0/17 (0.0%)	0/27 (0.0%)
Week 4							
Evaluated	310	11	42	34	28	16	26
Retained	301/310 (97.1%)	11/11 (100.0%)	41/42 (97.6%)	33/34 (97.1%)	28/28 (100.0%)	15/16 (93.8%)	25/26 (96.2%)
On Time	275/301 (91.4%)	8/11 (72.7%)	37/41 (90.2%)	32/33 (97.0%)	25/28 (89.3%)	15/15 (100.0%)	22/25 (88.0%)
Late	26/301 (8.6%)	3/11 (27.3%)	4/41 (9.8%)	1/33 (3.0%)	3/28 (10.7%)	0/15 (0.0%)	3/25 (12.0%)
MissedVisit	7/310 (2.3%)	0/11 (0.0%)	1/42 (2.4%)	1/34 (2.9%)	0/28 (0.0%)	1/16 (6.3%)	1/26 (3.8%)
Lost to Follow-up	2/310 (0.6%)	0/11 (0.0%)	0/42 (0.0%)	0/34 (0.0%)	0/28 (0.0%)	0/16 (0.0%)	0/26 (0.0%)
Week 8							
Evaluated	284	8	39	31	28	15	22
Retained	276/284 (97.2%)	8/8 (100.0%)	39/39 (100.0%)	31/31 (100.0%)	28/28 (100.0%)	14/15 (93.3%)	20/22 (90.9%)
On Time	257/276 (93.1%)	6/8 (75.0%)	36/39 (92.3%)	29/31 (93.5%)	26/28 (92.9%)	14/14 (100.0%)	19/20 (95.0%)
Late	19/276 (6.9%)	2/8 (25.0%)	3/39 (7.7%)	2/31 (6.5%)	2/28 (7.1%)	0/14 (0.0%)	1/20 (5.0%)
MissedVisit	6/284 (2.1%)	0/8 (0.0%)	0/39 (0.0%)	0/31 (0.0%)	0/28 (0.0%)	1/15 (6.7%)	2/22 (9.1%)
Lost to Follow-up	2/284 (0.7%)	0/8 (0.0%)	0/39 (0.0%)	0/31 (0.0%)	0/28 (0.0%)	0/15 (0.0%)	0/22 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.2 (03SEP2013,16:35)

HPTN 069 - Maraviroc Phase II PrEP

Data as of September 2, 2013

Retention by Study Visit and Site

MALE

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	347	14	46	34	30	17	29
Week 16							
Evaluated	222	3	32	30	19	12	19
Retained	213/222 (95.9%)	3/3 (100.0%)	30/32 (93.8%)	30/30 (100.0%)	19/19 (100.0%)	11/12 (91.7%)	17/19 (89.5%)
On Time	199/213 (93.4%)	3/3 (100.0%)	28/30 (93.3%)	28/30 (93.3%)	19/19 (100.0%)	11/11 (100.0%)	15/17 (88.2%)
Late	14/213 (6.6%)	0/3 (0.0%)	2/30 (6.7%)	2/30 (6.7%)	0/19 (0.0%)	0/11 (0.0%)	2/17 (11.8%)
MissedVisit	7/222 (3.2%)	0/3 (0.0%)	2/32 (6.3%)	0/30 (0.0%)	0/19 (0.0%)	1/12 (8.3%)	2/19 (10.5%)
Lost to Follow-up	2/222 (0.9%)	0/3 (0.0%)	0/32 (0.0%)	0/30 (0.0%)	0/19 (0.0%)	0/12 (0.0%)	0/19 (0.0%)
Week 24							
Evaluated	160	2	23	24	15	8	14
Retained	151/160 (94.4%)	2/2 (100.0%)	23/23 (100.0%)	23/24 (95.8%)	15/15 (100.0%)	7/8 (87.5%)	12/14 (85.7%)
On Time	131/151 (86.8%)	2/2 (100.0%)	15/23 (65.2%)	18/23 (78.3%)	14/15 (93.3%)	6/7 (85.7%)	11/12 (91.7%)
Late	20/151 (13.2%)	0/2 (0.0%)	8/23 (34.8%)	5/23 (21.7%)	1/15 (6.7%)	1/7 (14.3%)	1/12 (8.3%)
MissedVisit	6/160 (3.8%)	0/2 (0.0%)	0/23 (0.0%)	1/24 (4.2%)	0/15 (0.0%)	1/8 (12.5%)	2/14 (14.3%)
Lost to Follow-up	3/160 (1.9%)	0/2 (0.0%)	0/23 (0.0%)	0/24 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/14 (0.0%)
Week 32							
Evaluated	97	2	12	15	10	6	8
Retained	91/97 (93.8%)	2/2 (100.0%)	11/12 (91.7%)	14/15 (93.3%)	10/10 (100.0%)	5/6 (83.3%)	8/8 (100.0%)
On Time	73/91 (80.2%)	2/2 (100.0%)	6/11 (54.5%)	12/14 (85.7%)	10/10 (100.0%)	4/5 (80.0%)	3/8 (37.5%)
Late	18/91 (19.8%)	0/2 (0.0%)	5/11 (45.5%)	2/14 (14.3%)	0/10 (0.0%)	1/5 (20.0%)	5/8 (62.5%)
MissedVisit	4/97 (4.1%)	0/2 (0.0%)	0/12 (0.0%)	1/15 (6.7%)	0/10 (0.0%)	1/6 (16.7%)	0/8 (0.0%)
Lost to Follow-up	2/97 (2.1%)	0/2 (0.0%)	1/12 (8.3%)	0/15 (0.0%)	0/10 (0.0%)	0/6 (0.0%)	0/8 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.

Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.2 (03SEP2013,16:35)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	347	14	46	34	30	17	29
Week 40							
Evaluated	56	1	8	10	7	4	5
Retained	52/56 (92.9%)	1/1 (100.0%)	7/8 (87.5%)	9/10 (90.0%)	7/7 (100.0%)	4/4 (100.0%)	5/5 (100.0%)
On Time	45/52 (86.5%)	1/1 (100.0%)	4/7 (57.1%)	8/9 (88.9%)	7/7 (100.0%)	4/4 (100.0%)	3/5 (60.0%)
Late	7/52 (13.5%)	0/1 (0.0%)	3/7 (42.9%)	1/9 (11.1%)	0/7 (0.0%)	0/4 (0.0%)	2/5 (40.0%)
MissedVisit	2/56 (3.6%)	0/1 (0.0%)	0/8 (0.0%)	1/10 (10.0%)	0/7 (0.0%)	0/4 (0.0%)	0/5 (0.0%)
Lost to Follow-up	2/56 (3.6%)	0/1 (0.0%)	1/8 (12.5%)	0/10 (0.0%)	0/7 (0.0%)	0/4 (0.0%)	0/5 (0.0%)
Week 48							
Evaluated	14	0	2	8	1	1	1
Retained	12/14 (85.7%)	0/0 (-%)	1/2 (50.0%)	7/8 (87.5%)	1/1 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
On Time	12/12 (100.0%)	0/0 (-%)	1/1 (100.0%)	7/7 (100.0%)	1/1 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Late	0/12 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/7 (0.0%)	0/1 (0.0%)	0/1 (0.0%)	0/1 (0.0%)
MissedVisit	1/14 (7.1%)	0/0 (-%)	0/2 (0.0%)	1/8 (12.5%)	0/1 (0.0%)	0/1 (0.0%)	0/1 (0.0%)
Lost to Follow-up	1/14 (7.1%)	0/0 (-%)	1/2 (50.0%)	0/8 (0.0%)	0/1 (0.0%)	0/1 (0.0%)	0/1 (0.0%)
Week 49							
Evaluated	8	0	1	6	0	1	0
Retained	8/8 (100.0%)	0/0 (-%)	1/1 (100.0%)	6/6 (100.0%)	0/0 (-%)	1/1 (100.0%)	0/0 (-%)
On Time	8/8 (100.0%)	0/0 (-%)	1/1 (100.0%)	6/6 (100.0%)	0/0 (-%)	1/1 (100.0%)	0/0 (-%)
Late	0/8 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/6 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)
MissedVisit	0/8 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/6 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)
Lost to Follow-up	0/8 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/6 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.2 (03SEP2013,16:35)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
MALE**

	Total	Philadelphia, PA	Pittsburgh, PA	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	347	32	15	41	13	26	50
Week 2							
Evaluated	331	30	14	38	11	25	50
Retained	308/331 (93.1%)	28/30 (93.3%)	14/14 (100.0%)	34/38 (89.5%)	10/11 (90.9%)	24/25 (96.0%)	49/50 (98.0%)
On Time	305/308 (99.0%)	28/28 (100.0%)	14/14 (100.0%)	34/34 (100.0%)	9/10 (90.0%)	24/24 (100.0%)	49/49 (100.0%)
Late	3/308 (1.0%)	0/28 (0.0%)	0/14 (0.0%)	0/34 (0.0%)	1/10 (10.0%)	0/24 (0.0%)	0/49 (0.0%)
MissedVisit	21/331 (6.3%)	1/30 (3.3%)	0/14 (0.0%)	4/38 (10.5%)	1/11 (9.1%)	0/25 (0.0%)	1/50 (2.0%)
Lost to Follow-up	2/331 (0.6%)	1/30 (3.3%)	0/14 (0.0%)	0/38 (0.0%)	0/11 (0.0%)	1/25 (4.0%)	0/50 (0.0%)
Week 4							
Evaluated	310	29	12	34	11	22	45
Retained	301/310 (97.1%)	28/29 (96.6%)	12/12 (100.0%)	32/34 (94.1%)	11/11 (100.0%)	20/22 (90.9%)	45/45 (100.0%)
On Time	275/301 (91.4%)	27/28 (96.4%)	12/12 (100.0%)	27/32 (84.4%)	10/11 (90.9%)	20/20 (100.0%)	40/45 (88.9%)
Late	26/301 (8.6%)	1/28 (3.6%)	0/12 (0.0%)	5/32 (15.6%)	1/11 (9.1%)	0/20 (0.0%)	5/45 (11.1%)
MissedVisit	7/310 (2.3%)	0/29 (0.0%)	0/12 (0.0%)	2/34 (5.9%)	0/11 (0.0%)	1/22 (4.5%)	0/45 (0.0%)
Lost to Follow-up	2/310 (0.6%)	1/29 (3.4%)	0/12 (0.0%)	0/34 (0.0%)	0/11 (0.0%)	1/22 (4.5%)	0/45 (0.0%)
Week 8							
Evaluated	284	29	11	31	10	19	41
Retained	276/284 (97.2%)	27/29 (93.1%)	11/11 (100.0%)	29/31 (93.5%)	10/10 (100.0%)	18/19 (94.7%)	41/41 (100.0%)
On Time	257/276 (93.1%)	27/27 (100.0%)	11/11 (100.0%)	23/29 (79.3%)	10/10 (100.0%)	18/18 (100.0%)	38/41 (92.7%)
Late	19/276 (6.9%)	0/27 (0.0%)	0/11 (0.0%)	6/29 (20.7%)	0/10 (0.0%)	0/18 (0.0%)	3/41 (7.3%)
MissedVisit	6/284 (2.1%)	1/29 (3.4%)	0/11 (0.0%)	2/31 (6.5%)	0/10 (0.0%)	0/19 (0.0%)	0/41 (0.0%)
Lost to Follow-up	2/284 (0.7%)	1/29 (3.4%)	0/11 (0.0%)	0/31 (0.0%)	0/10 (0.0%)	1/19 (5.3%)	0/41 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
MALE**

	Total	Philadelphia, PA	Pittsburgh, PA	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	347	32	15	41	13	26	50
Week 16							
Evaluated	222	25	8	25	9	15	25
Retained	213/222 (95.9%)	24/25 (96.0%)	8/8 (100.0%)	23/25 (92.0%)	9/9 (100.0%)	14/15 (93.3%)	25/25 (100.0%)
On Time	199/213 (93.4%)	23/24 (95.8%)	8/8 (100.0%)	20/23 (87.0%)	9/9 (100.0%)	14/14 (100.0%)	21/25 (84.0%)
Late	14/213 (6.6%)	1/24 (4.2%)	0/8 (0.0%)	3/23 (13.0%)	0/9 (0.0%)	0/14 (0.0%)	4/25 (16.0%)
MissedVisit	7/222 (3.2%)	0/25 (0.0%)	0/8 (0.0%)	2/25 (8.0%)	0/9 (0.0%)	0/15 (0.0%)	0/25 (0.0%)
Lost to Follow-up	2/222 (0.9%)	1/25 (4.0%)	0/8 (0.0%)	0/25 (0.0%)	0/9 (0.0%)	1/15 (6.7%)	0/25 (0.0%)
Week 24							
Evaluated	160	23	4	20	4	9	14
Retained	151/160 (94.4%)	22/23 (95.7%)	4/4 (100.0%)	18/20 (90.0%)	4/4 (100.0%)	7/9 (77.8%)	14/14 (100.0%)
On Time	131/151 (86.8%)	20/22 (90.9%)	4/4 (100.0%)	16/18 (88.9%)	4/4 (100.0%)	7/7 (100.0%)	14/14 (100.0%)
Late	20/151 (13.2%)	2/22 (9.1%)	0/4 (0.0%)	2/18 (11.1%)	0/4 (0.0%)	0/7 (0.0%)	0/14 (0.0%)
MissedVisit	6/160 (3.8%)	0/23 (0.0%)	0/4 (0.0%)	1/20 (5.0%)	0/4 (0.0%)	1/9 (11.1%)	0/14 (0.0%)
Lost to Follow-up	3/160 (1.9%)	1/23 (4.3%)	0/4 (0.0%)	1/20 (5.0%)	0/4 (0.0%)	1/9 (11.1%)	0/14 (0.0%)
Week 32							
Evaluated	97	16	2	13	1	5	7
Retained	91/97 (93.8%)	15/16 (93.8%)	2/2 (100.0%)	11/13 (84.6%)	1/1 (100.0%)	5/5 (100.0%)	7/7 (100.0%)
On Time	73/91 (80.2%)	14/15 (93.3%)	2/2 (100.0%)	9/11 (81.8%)	0/1 (0.0%)	5/5 (100.0%)	6/7 (85.7%)
Late	18/91 (19.8%)	1/15 (6.7%)	0/2 (0.0%)	2/11 (18.2%)	1/1 (100.0%)	0/5 (0.0%)	1/7 (14.3%)
MissedVisit	4/97 (4.1%)	1/16 (6.3%)	0/2 (0.0%)	1/13 (7.7%)	0/1 (0.0%)	0/5 (0.0%)	0/7 (0.0%)
Lost to Follow-up	2/97 (2.1%)	0/16 (0.0%)	0/2 (0.0%)	1/13 (7.7%)	0/1 (0.0%)	0/5 (0.0%)	0/7 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.2 (03SEP2013,16:35)

HPTN 069 - Maraviroc Phase II PrEP

Data as of September 2, 2013

Retention by Study Visit and Site

MALE

	Total	Philadelphia, PA	Pittsburgh, PA	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	347	32	15	41	13	26	50
Week 40							
Evaluated	56	12	0	6	0	2	1
Retained	52/56 (92.9%)	11/12 (91.7%)	0/0 (-%)	5/6 (83.3%)	0/0 (-%)	2/2 (100.0%)	1/1 (100.0%)
On Time	45/52 (86.5%)	11/11 (100.0%)	0/0 (-%)	5/5 (100.0%)	0/0 (-%)	1/2 (50.0%)	1/1 (100.0%)
Late	7/52 (13.5%)	0/11 (0.0%)	0/0 (-%)	0/5 (0.0%)	0/0 (-%)	1/2 (50.0%)	0/1 (0.0%)
MissedVisit	2/56 (3.6%)	1/12 (8.3%)	0/0 (-%)	0/6 (0.0%)	0/0 (-%)	0/2 (0.0%)	0/1 (0.0%)
Lost to Follow-up	2/56 (3.6%)	0/12 (0.0%)	0/0 (-%)	1/6 (16.7%)	0/0 (-%)	0/2 (0.0%)	0/1 (0.0%)
Week 48							
Evaluated	14	1	0	0	0	0	0
Retained	12/14 (85.7%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
On Time	12/12 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Late	0/12 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
MissedVisit	1/14 (7.1%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Lost to Follow-up	1/14 (7.1%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 49							
Evaluated	8	0	0	0	0	0	0
Retained	8/8 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
On Time	8/8 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Late	0/8 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
MissedVisit	0/8 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Lost to Follow-up	0/8 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.

Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.2 (03SEP2013,16:35)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
FEMALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	37	0	8	3	1	0	3
Week 2							
Evaluated	31	0	8	3	1	0	2
Retained	29/31 (93.5%)	0/0 (-%)	7/8 (87.5%)	3/3 (100.0%)	1/1 (100.0%)	0/0 (-%)	2/2 (100.0%)
On Time	28/29 (96.6%)	0/0 (-%)	7/7 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	0/0 (-%)	1/2 (50.0%)
Late	1/29 (3.4%)	0/0 (-%)	0/7 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	1/2 (50.0%)
MissedVisit	2/31 (6.5%)	0/0 (-%)	1/8 (12.5%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/2 (0.0%)
Lost to Follow-up	0/31 (0.0%)	0/0 (-%)	0/8 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/2 (0.0%)
Week 4							
Evaluated	28	0	8	3	1	0	1
Retained	27/28 (96.4%)	0/0 (-%)	8/8 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	0/0 (-%)	1/1 (100.0%)
On Time	26/27 (96.3%)	0/0 (-%)	8/8 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	0/0 (-%)	1/1 (100.0%)
Late	1/27 (3.7%)	0/0 (-%)	0/8 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)
MissedVisit	1/28 (3.6%)	0/0 (-%)	0/8 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)
Lost to Follow-up	0/28 (0.0%)	0/0 (-%)	0/8 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)
Week 8							
Evaluated	21	0	3	3	1	0	1
Retained	21/21 (100.0%)	0/0 (-%)	3/3 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	0/0 (-%)	1/1 (100.0%)
On Time	20/21 (95.2%)	0/0 (-%)	3/3 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	0/0 (-%)	1/1 (100.0%)
Late	1/21 (4.8%)	0/0 (-%)	0/3 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)
MissedVisit	0/21 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)
Lost to Follow-up	0/21 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/3 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
FEMALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
Week 16							
Evaluated	8	0	0	1	1	0	0
Retained	8/8 (100.0%)	0/0 (-%)	0/0 (-%)	1/1 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)
On Time	8/8 (100.0%)	0/0 (-%)	0/0 (-%)	1/1 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)
Late	0/8 (0.0%)	0/0 (-%)	0/0 (-%)	0/1 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)
MissedVisit	0/8 (0.0%)	0/0 (-%)	0/0 (-%)	0/1 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)
Lost to Follow-up	0/8 (0.0%)	0/0 (-%)	0/0 (-%)	0/1 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

HPTN 069 - Maraviroc Phase II PrEP

Data as of September 2, 2013

Retention by Study Visit and Site

FEMALE

	Total	Newark, NJ	Philadelphia, PA	Pittsburgh, PA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	37	8	5	0	3	2	4
Week 2							
Evaluated	31	7	3	0	3	1	3
Retained	29/31 (93.5%)	6/7 (85.7%)	3/3 (100.0%)	0/0 (-%)	3/3 (100.0%)	1/1 (100.0%)	3/3 (100.0%)
On Time	28/29 (96.6%)	6/6 (100.0%)	3/3 (100.0%)	0/0 (-%)	3/3 (100.0%)	1/1 (100.0%)	3/3 (100.0%)
Late	1/29 (3.4%)	0/6 (0.0%)	0/3 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/1 (0.0%)	0/3 (0.0%)
MissedVisit	2/31 (6.5%)	1/7 (14.3%)	0/3 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/1 (0.0%)	0/3 (0.0%)
Lost to Follow-up	0/31 (0.0%)	0/7 (0.0%)	0/3 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/1 (0.0%)	0/3 (0.0%)
Week 4							
Evaluated	28	6	3	0	3	1	2
Retained	27/28 (96.4%)	5/6 (83.3%)	3/3 (100.0%)	0/0 (-%)	3/3 (100.0%)	1/1 (100.0%)	2/2 (100.0%)
On Time	26/27 (96.3%)	5/5 (100.0%)	2/3 (66.7%)	0/0 (-%)	3/3 (100.0%)	1/1 (100.0%)	2/2 (100.0%)
Late	1/27 (3.7%)	0/5 (0.0%)	1/3 (33.3%)	0/0 (-%)	0/3 (0.0%)	0/1 (0.0%)	0/2 (0.0%)
MissedVisit	1/28 (3.6%)	1/6 (16.7%)	0/3 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/1 (0.0%)	0/2 (0.0%)
Lost to Follow-up	0/28 (0.0%)	0/6 (0.0%)	0/3 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/1 (0.0%)	0/2 (0.0%)
Week 8							
Evaluated	21	6	3	0	2	1	1
Retained	21/21 (100.0%)	6/6 (100.0%)	3/3 (100.0%)	0/0 (-%)	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
On Time	20/21 (95.2%)	6/6 (100.0%)	2/3 (66.7%)	0/0 (-%)	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Late	1/21 (4.8%)	0/6 (0.0%)	1/3 (33.3%)	0/0 (-%)	0/2 (0.0%)	0/1 (0.0%)	0/1 (0.0%)
MissedVisit	0/21 (0.0%)	0/6 (0.0%)	0/3 (0.0%)	0/0 (-%)	0/2 (0.0%)	0/1 (0.0%)	0/1 (0.0%)
Lost to Follow-up	0/21 (0.0%)	0/6 (0.0%)	0/3 (0.0%)	0/0 (-%)	0/2 (0.0%)	0/1 (0.0%)	0/1 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.

Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.2 (03SEP2013,16:35)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of September 2, 2013**

**Retention by Study Visit and Site
FEMALE**

	Total	Newark, NJ	Philadelphia, PA	Pittsburgh, PA	San Juan, PR	Seattle, WA	Washington DC
Week 16							
Evaluated	8	5	1	0	0	0	0
Retained	8/8 (100.0%)	5/5 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
On Time	8/8 (100.0%)	5/5 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Late	0/8 (0.0%)	0/5 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
MissedVisit	0/8 (0.0%)	0/5 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Lost to Follow-up	0/8 (0.0%)	0/5 (0.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.